Event Details
Date: December 9–12, 2025
Location: Henry B. Gonzalez Convention Center, 900 E Market St, San Antonio, TX 78205
Event Website: https://sabcs.org
Event Overview
Cizzle Bio will attend the 2025 San Antonio Breast Cancer Symposium, a premier global gathering that brings together researchers, clinicians, patient advocates, and industry partners from around the world to share the latest advances in breast cancer biology, prevention, diagnosis, treatment, and survivorship.
The program spans a wide range of formats including plenary lectures, case discussions, slide and poster presentations, educational sessions, translational workshops, and industry exhibits. Topics include experimental biology, translational science, clinical therapy updates, risk assessment, liquid biopsy, and insights into both early-stage and metastatic breast cancer.
SABCS 2025 expects thousands of attendees — including physician-scientists, breast care providers, basic and translational researchers, and patient advocates — representing over 100 countries.
Why Attend
Access cutting-edge research and late-breaking clinical trial data spanning the full breast cancer continuum from prevention to therapy.
Engage with global experts, researchers, clinicians, and advocates — an ideal opportunity for networking and collaboration across disciplines.
Explore advances in diagnostics, biomarker research, liquid biopsy, and translational science — areas closely aligned with Cizzle Bio’s mission of early detection and diagnostic innovation.
Participate either in-person in San Antonio or virtually, giving flexibility to our team and collaborators.
Cizzle Bio’s Focus
As a company committed to advancing early detection biomarkers and next-generation diagnostics, Cizzle Bio values SABCS for its comprehensive coverage of breast cancer research — from fundamental biology to clinical applications. Attendance at this symposium supports our ongoing engagement with the oncology community, keeps us current on emerging scientific trends, and fosters potential collaborations that advance our mission to improve early cancer detection and patient outcomes.